Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Docetaxel in combination with fluorouracil for advanced solid tumors

H A Burris1

  • 1Oncology Service, Brooke Army Medical Center Fort Sam Houston, Texas, USA.

Oncology (Williston Park, N.Y.)
|August 1, 1997
PubMed
Summary

The combination of docetaxel and fluorouracil (5-FU) shows significant synergy in preclinical models. Phase I studies suggest optimal dosing for further clinical trials in advanced cancers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial.

ESMO open·2024
Same author

Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Same author

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2017

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Preclinical studies in murine tumor models indicate a highly synergistic effect between docetaxel and fluorouracil (5-FU).
  • This combination therapy is being investigated for advanced solid tumors.

Purpose of the Study:

  • To determine recommended doses for Phase II studies of docetaxel and 5-FU combination therapy.
  • To evaluate the safety and efficacy of this combination in ongoing Phase I/II and II clinical trials.

Main Methods:

  • Phase I clinical studies were conducted to establish recommended dosages for docetaxel and 5-FU.
  • Dose-limiting toxicities such as neutropenia and mucositis were identified.
  • Ongoing studies are evaluating the combination in metastatic breast cancer and head and neck cancer.

Main Results:

  • Two potential dosing regimens for Phase II studies were identified: docetaxel (60 mg/m2) with 5-FU bolus (300 mg/m2) and docetaxel (85 mg/m2) with continuous infusion 5-FU (750 mg/m2/day).
  • Neutropenia and mucositis were confirmed as dose-limiting toxicities.
  • Preliminary results from ongoing trials are encouraging.

Conclusions:

  • The combination of docetaxel and 5-FU demonstrates promising synergistic activity and manageable toxicities.
  • Further clinical investigation in Phase II and beyond is warranted for advanced cancers, including metastatic breast and head and neck cancers.

Related Experiment Videos